OrthoPediatrics Corp. (NASDAQ:KIDS) CEO David R. Bailey Sells 6,620 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the transaction, the chief executive officer now directly owns 319,155 shares in the company, valued at $7,934,193.30. This represents a 2.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

OrthoPediatrics Stock Performance

NASDAQ:KIDS opened at $25.42 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The company has a market cap of $617.38 million, a price-to-earnings ratio of -20.67 and a beta of 1.22. OrthoPediatrics Corp. has a 1 year low of $21.02 and a 1 year high of $35.99. The stock’s 50 day simple moving average is $24.79 and its two-hundred day simple moving average is $25.53.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. The business had revenue of $52.67 million during the quarter, compared to analyst estimates of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter last year, the business earned ($0.23) earnings per share. As a group, equities analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Truist Financial dropped their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Stifel Nicolaus cut their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a research report on Wednesday, March 5th.

Institutional Investors Weigh In On OrthoPediatrics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KIDS. AWM Investment Company Inc. increased its position in shares of OrthoPediatrics by 14.8% during the 4th quarter. AWM Investment Company Inc. now owns 516,794 shares of the company’s stock valued at $11,979,000 after purchasing an additional 66,779 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of OrthoPediatrics by 76.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 19,863 shares of the company’s stock worth $460,000 after purchasing an additional 8,631 shares during the period. Point72 Asset Management L.P. bought a new position in OrthoPediatrics during the 4th quarter valued at about $7,450,000. Numerai GP LLC purchased a new stake in OrthoPediatrics in the 4th quarter worth about $372,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in OrthoPediatrics by 25.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 65,292 shares of the company’s stock worth $1,513,000 after purchasing an additional 13,270 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.